MAST1 and neoplasm: demonstrated that treatment with lestaurtinib, an inhibitor of MAST1, fully revived cisplatin sensitivity in the dexamethasone-treated (prior cisplatin-resistant group) and even further attenuated tumor growth compared to the group treated with cisplatin alone (22).